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Secondary data in diabetes surveillance – co-operation projects and 
definition of references on the documented prevalence of diabetes
Abstract
In addition to the Robert Koch Institute’s health surveys, analyses of secondary data are essential to successfully developing 
a regular and comprehensive description of the progression of diabetes as part of the Robert Koch Institute’s diabetes 
surveillance. Mainly, this is due to the large sample size and the fact that secondary data are routinely collected, which 
allows for highly stratified analyses in short time intervals. The fragmented availability of data means that various sources 
of secondary data are required in order to provide data for the indicators in the four fields of action for diabetes surveillance. 
Thus, a milestone in the project was to check the suitability of different data sources for their usability and to carry out 
analyses. Against this backdrop, co-operation projects were specifically funded in the context of diabetes surveillance.
This article presents the results that were achieved in co-operation projects between 2016 and 2018 that focused on a 
range of topics: from evaluating the usability of secondary data to statistically modelling the development of epidemiological 
indices. Moreover, based on the data of the around 70 million people covered by statutory health insurance, an initial 
estimate was calculated for the documented prevalence of type 2 diabetes for the years 2010 and 2011. To comparably 
integrate these prevalences over the years in diabetes surveillance, a reference definition was established with external 
expertise.
 DIABETES SURVEILLANCE · DIABETES MELLITUS · SECONDARY DATA · EPIDEMIOLOGY · PUBLIC HEALTH 
1. Introduction
A pilot project to establish diabetes surveillance at the 
Robert Koch Institute (RKI) was launched in 2016. This step 
highlights diabetes mellitus’ great relevance to public 
health as a disease and cause of complications. Based on 
indicators agreed upon in consensus by experts, in future 
diabetes surveillance will report on diabetes-relevant devel-
opments as defined by its conceptual framework [1]. The 
presentation of results based on these indicators makes 
use of further data sources in addition to the data provid-
ed by the RKI in the context of health monitoring (primary 
data). The main objective of health monitoring is to pro-
vide representative information on the trends for the most 
important diseases, health behaviour and subjective assess-
ments of the health of the population in Germany stratified 
by age, gender and socioeconomic status (see the article 
on Social inequality and diabetes mellitus in this issue)[2].
Conducting interview and examination surveys is 
time-consuming because the content must be coordinated 
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indicators, their definition and the sources of data has been 
published on the RKI website [3]. 11 indicators that rely 
mainly on RKI health monitoring data also require sec-
ondary data. The diabetes surveillance data model (Figure 1) 
therefore includes RKI health monitoring, type 1 diabetes 
registry data (see the article on Type 1 diabetes in adults 
and type 2 diabetes in children and adolescents in this 
issue) as well as claims data of the statutory health insur-
ance. This latter data is primarily collected for accounting 
and only secondarily used in scientific analyses, which is 
why such data has become known as secondary data [4]. 
Secondary data is process-produced data and therefore 
contains only limited information on socioeconomic sta-
tus, subjective health, risk factors or undiagnosed diseases. 
The advantages of this data, however, are large samples 
and the availability of a constant inflow of new data.
Data from the social security system provides the core 
of secondary data, i.e. the data from the main providers of 
outpatient, inpatient and rehabilitative medicine: statutory 
health insurances (GKV) and the German pension insur-
ance (DRV). Due to Germany’s regionally segregated health 
care structure, much of this routinely collected data is not 
centrally available, is processed by different institutions 
and therefore not always equally available to research [5]. 
Data on the provision of rehabilitation services through 
DRV for example are kept by the German pension insur-
ance. Evaluating the use of medical rehabilitation services 
by diabetes patients is therefore only possible based on 
this data [6]. And GKV data is for example segregated by 
insurance providers and sector. While some health insur-
ances do use the data of insured persons to calculate dis-
ease prevalences, the demographic and socioeconomic 
with each other, and organisational planning and meticu-
lous quality and data protection procedures also take time. 
Furthermore, as the objective is to collect information as 
efficiently as possible, the number of cases in primary stud-
ies is limited. To fully implement the objective of surveil-
lance, i.e. provide in-depth stratification for specific indi-
cators and at short time intervals, requires further sources 
of data. Reviewing potential sources of data, modes of 
accessing this data and adequate analyses were therefore 
key project tasks in the establishment of diabetes surveil-
lance. To achieve these objectives, tenders for co-operation 
projects were organised in order to help define evaluation 
potentials, identify and close data gaps, and reveal options 
for data analysis for the entire duration of the project.
Out of the 40 indicators of diabetes surveillance 
14 require only secondary data. A detailed description of 
Figure 1 
Data model of diabetes surveillance
Own diagram 
RKI = Robert Koch Institute 
GNHIES98 = German National Health Survey 1998
DEGS1 = German Health Interview and Examination Survey for Adults (2008-2011)
GEDA = German Health Update
DaTraV = Data according to the Data Transparency Regulations
DRV = German pension insurance
DRG statistic = Diagnosis-Related Groups Statistic




(DaTraV, DRV, DRG statistic, Zi)
Official statistics
(cause of death statistics, 
disease-related cost accounts)
RKI health surveys
(GNHIES98, DEGS1, GEDA, 
Add-on Survey)
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more difficult. Furthermore, particularly with diabetes, the 
differentiation between the different forms of the disease 
in analyses of secondary data is tied to a set of assump-
tions. Frequently one finds unspecific or aetiologically 
mutually exclusive diagnoses, such as a diagnosis of 
type 1 and type 2 diabetes simultaneously coded together 
[10]. A reference definition, which will be applied to DaTraV 
data, aims to increase the reliability, transparency and com-
parability of documented prevalence within the framework 
of diabetes surveillance. The definition of prevalence also 
provides the basis to determine further indicators such as 
those of mortality and incidence.
This article provides an overview of the results of the 
co-operation projects developed and co-operation partners 
found in the context of diabetes surveillance, who have all 
contributed significantly to the development of this project. 
We also present initial results on the prevalence of type 2 
diabetes based on DaTraV data. The critical review of and 
experiences with this first set of results led to the definition 
of a frame of reference, which we also present here and 
which will provide the foundation for future diabetes surveil-
lance reporting of documented prevalence and the calcu-
lation of further indicators.
2.  Methodology
Since 2016, diabetes surveillance has published tender 
notices annually to promote co-operation projects. Suit-
able projects were selected based on specifically developed, 
standardised application and evaluation criteria, which 
were annually adapted in accordance with the stage of the 
project. The main criteria by which to evaluate the projects 
differences, as well as the differences in health risks 
between those insured by different insurers make compar-
isons difficult [5]. This makes it difficult to generalise, for 
example on the prevalence of diabetes among all people 
with statutory health insurance, and means prevalence can 
only be estimated based on assumptions [7].
The Central Research Institute of Ambulatory Health 
Care (Zi) in Germany holds a complete set of outpatient 
claims data for all people covered by statutory health insur-
ance. However, this data does not contain information on 
people covered by statutory health insurance with no out-
patient consultations and totally lacks data on inpatient 
care [8]. Information on all people covered by statutory 
health insurance is contained in the data set held by the 
German Institute of Medical Documentation and Informa-
tion (DIMDI) on the basis of Germany’s Data Transparency 
Regulations (DaTraV) [9]. However, this data too has its 
limitations. While it contains complete data on out- and 
inpatient diagnoses as well as prescribed medicines, it pro-
vides no information on inpatient or outpatient medical 
services. Furthermore, this data currently comes with a 
four-year delay and can so far only be evaluated regionally 
for individual reporting years. Moreover, neither the Zi nor 
the DIMDI data set provide information on people covered 
by private insurance. Info box 1 describes the data provided 
by DaTraV and its usability in surveillance systems, as well 
as an overview of planned reforms. 
Beyond the problems posed by fragmented and incom-
plete data described above, the criteria to define diabetes 
in routine data (selection criteria) also vary. Differences in 
selection criteria, which can be justified based on content, 
produce different results and make comparability over time 
Info box 1: 
Data by the Data Transparency Regulations (DaTraV) 
The data processing unit at the Institute of Med-
ical Documentation and Information (DIMDI) can 
provide analyses based on the routine data of the 
around 70 million people covered by statutory 
health insurance (DaTraV data), which help plan, 
manage and assess the needs of the German 
health care system while ensuring the protection 
of the identity of ensured persons. DaTraV data 
can be evaluated across sectors of care and health 
insurance companies. It allows long-term assess-
ments of disease progress for individual patients. 
As various publications have shown, using DaTraV 
data in the surveillance of noncommunicable dis-
eases in particular principally makes sense. Yet 
there is room for improvements and an amend-
ment to the data transparency regulations is 
planned. Changes will probably include
  Transferral of the diagnoses and medication 
data from the morbidity-oriented risk structure 
compensation scheme (Morbi-RSA), also of 
deceased individuals by the German Federal 
Insurance Office, 
  reducing the delay in data provision from four 
to two years.
One aim is to reduce the current processing time 
for applications. Based on an external evaluation 
of the organisation, an increase of staff was 
applied for. Already, data on place of residence for 
2009, 2010 and 2011 are available for analyses. 
From 2020, it will be possible to continuously 
analyse reporting years regionally by postal codes.
Journal of Health Monitoring
Journal of Health Monitoring 2019 4(2)
Secondary data in diabetes surveillance – co-operation projects and definition of references on the documented prevalence of diabetes
53
FOCUS
3.1  Results of co-operation projects
Table 1 presents the authors of the co-operation projects, 
the indicators or contributions they worked on and the 
benefits these provide to diabetes surveillance.
3.1.1  Time series on amputations and hospitalisation in 
patients with diabetes
Hospitalisations due to lower limb amputations (major 
amputations) or other diabetes-related complications in 
diabetes patients are considered potentially preventable 
because diabetes can be controlled well with adequate 
structures for outpatient treatment. The Organisation for 
Economic Co-operation and Development (OECD) there-
fore uses hospitalisations as a population-related indicator 
that allows conclusions to be drawn on availability and 
quality of outpatient care [12]. These indicators are calcu-
lated for diabetes surveillance based on the Diagnosis-Re-
lated Groups Statistic (DRG statistic). 76,139 women with 
diabetes were hospitalised due to complications and 2,560 
had amputations in Germany in 2016; for men, the figures 
were 108,386 hospitalisations due to complications and 
5,402 amputations. After age standardisation using the 
German standard population in 2005, the number of hos-
pital cases in the female population declined over time 
from 234 cases per 100,000 inhabitants in 2005 to 174 cas-
es per 100,000 inhabitants in 2016. For men, the decrease 
was from 311 cases per 100,000 inhabitants in 2005 to 302 
cases per 100,000 inhabitants in 2016 (Figure 2). The 
amputation rate for women during this same period 
dropped from 11.6 cases per 100,000 inhabitants to 
5.4 cases per 100,000 inhabitants and from 23.0 cases per 
included a high public health relevance and easy integra-
tion within current surveillance, replicability of results, clar-
ity of the method and feasibility of the project proposal 
within a one year time span. Developing indicators, sifting 
suitable sources of data and selecting co-operation pro-
jects were all done in parallel.
During a workshop in March 2017 [11], co-operation 
partners presented the identified data sources and exem-
plary analyses from projects implemented during the first 
funding years and discussed them with experts. During the 
workshop, DaTraV data and the possibilities to analyse this 
data using the data processing unit of DIMDI were pre-
sented and discussed. At the same time, we applied for an 
initial DaTraV output data set to calculate the prevalence 
of diabetes in 2010 and 2011. The results for type 2 dia-
betes were presented stratified by age group and gender 
and put in the context of current literature. Based on a crit-
ical contextualisation of results, in co-operation with the 
data processing unit and external expertise, we developed 
the reference definition presented here, which will serve as 
a basis to calculate documented prevalence and further 
indicators.
3.  Results
In the following, the results of the cooperation projects 
from 2016 to 2018 will be presented first. Then the figures 
from the initial analysis of DaTraV data in the context of 
diabetes surveillance on the documented prevalence of 
type 2 diabetes during 2010 and 2011 will be presented and 
critically discussed. 
25 of 40 indicators of 
diabetes surveillance were 
either entirely or at least 
partially populated with 
secondary data.
Journal of Health Monitoring
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Adjusted for age and gender, a regional focus reveals 
particularly high rates of hospitalisations due to complica-
tions as well as for amputations in the former East German 
federal states with the exception of Berlin [13]. The great 
influence of diabetes prevalence is an important factor to 
100,000 inhabitants in 2005 to 14.9 cases per 100,000 
inhabitants in 2016 for men. The development of rates 
could indicate an improved quality of outpatient care for 
diabetes patients over time or otherwise a greater adher-
ence of patients to prescribed therapies [13]. 
Table 1 
Co-operation projects of diabetes 
surveillance, role within the project, 
authors and project description 
Own table 
Co-operation project Project year Contribution Use Authors 
Surveillance of ambulatory 
care-sensitive conditions  
in diabetes mellitus
2016 Amputations and hospitali-
sation (Section 3.1.1)
Regular presentation of  





Use of DMP documentation data 
for diabetes surveillance
No funding All indicators of DMP quality 
assurance (Section 3.1.2)
Exclusive evaluation of DMP 
data for diabetes surveillance
Bernd Hagen
Measuring quality of care based 
on routine data
2016-2017 Feasibility study on the 
potential of GKV data  
(Section 3.1.3)
Comprehensive estimate as a 
basis for definitions and anal-
yses based on secondary data 
Gunter Laux,  
Joachim Szecsenyi, 
Stephanie Kümmel
Projections of prevalence and 
incidence of diabetes in Germany
2017 Prevalence prognosis mod-
els (Section 3.1.4)
Innovative epidemiological 
methods to model different sce-
narios for the development of 
number of cases
Ralph Brinks,  
Thaddäus Tönnies, 
Annika Hoyer
Co-operation with the data  
processing department to 
improve the use of DaTraV data 
in epidemiological research
No funding Providing an overview of 
DaTraV data (Info box 1)
Reference evaluation with 
DaTraV data
Jochen Dreß
Feasibility study on the applica-
bility of data on obesogenic envi-
ronments in the surveillance of 
diabetes risk factors
2017 Obesity in tight-knit associ-
ation with environmental 
factors (Section 3.1.5)





Michael Laxy,  
Werner Maier
Updating of public health- 
relevant indices for diabetes  
surveillance and projections for 
the prevalence of diabetes and its 
limitations
2018 Disease burden figures 
(Section 3.1.6)
Use of biometric methods to 
estimate and provide prognoses 
for disease burden figures
Annika Hoyer,  
Thaddäus Tönnies, 
Ralph Brinks
Evaluation of St. Vincent targets 
based on diabetes mellitus- 
related complications: terminal 
renal insufficiency in patients 
with or without diabetes
2018 Renal replacement therapy 
and renal insufficiency  
(Section 3.1.7) 
Results from diverse data  
sources/development of  





GKV = statutory health insurance, DaTraV = Data according to the data transparency regulations, DMP = disease management program(s)
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chronically ill patients. A central feature of the disease man-
agement programs introduced for type 2 diabetes in 2003 
and type 1 diabetes in 2006 is the quarterly or semi-annu-
al documentation of standardised indicators by the partic-
ipating doctor’s surgeries. Based on these indicators the 
DMP defines a set of quality objectives to describe the qual-
ity of treatment for patients in DMP cross-sectionally and 
longitudinally. Across Germany, 4.4 million patients are 
registered in the diabetes DMP. On average, inscribed 
patients have been attended to for 7.5 years (type 2 dia-
betes) or 7.1 years (type 1 diabetes) in the DMPs of the 
Association of Statutory Health Insurance Physicians 
Nordrhein (KV-Nordrhein) [15]. This provides a large data 
set that permits differentiated findings on quality of care 
by age or duration of illness.
The usability of DMP data is limited particularly due to 
the following factors: 
(1) As participation in DMPs is generally voluntary and pro-
grams are only open to patients in statutory health insur-
ance who can still actively and independently handle 
their illness, selection effects are likely. 
(2) Documentation parameters and quality targets change 
over time, new indicators are created or indicators are 
replaced that have been used for many years. This cre-
ates gaps in surveillance over time. 
(3) Although the group of patients in the type 2 diabetes 
DMP is very large and probably very diverse regarding 
the duration of illness, there are no contractual bases 
to represent this diversity with regard to quality of care.
In spite of these limitations DMPs have provided a num-
ber of important results: diabetes DMPs reach a large pro-
take into account here, i.e. regional differences in preva-
lence already explain the differences in rates of amputa-
tions and hospitalisations [14].
Integrating the OECD indicators in diabetes surveillance 
is easily feasible in terms of methodology, however, the 
changing definitions of indicators are challenging for com-
parisons over time. Over the course of the co-operation 
project, for example, the definition of amputations changed 
to exclude patients who had died in hospital. When inter-
preting indicators regarding their spatial distribution, pre-
dictors such as the regional differences in diabetes preva-
lence or socioeconomic factors must be taken into account.
3.1.2 Potential uses for the Disease Management Programs
Disease Management Programs (DMP) are structured 
treatment programs for specific diseases that aim to 
improve treatment processes and the quality of care of 
Figure 2 
Hospitalisations and amputations over time 
(age standardised rates) for diabetes mellitus in 
Germany according to gender 
Source: Diagnosis-Related Groups Statistic 
(DRG statistic) 2005 to 2016















Over the course of the 
project, co-operation projects 
are promoted that specifi-
cally encourage the use of 
secondary sources of data.
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ther expand the indicator set. Consensus was found on 70 
quality indicators.
47 of these 70 indicators, i.e. over two thirds of the set, 
can be calculated using secondary data. Importantly, how-
ever, this always requires evaluating the validity of the 
underlying secondary data. In addition, adequate proce-
dures must ensure both internal and external validity, i.e. 
performing plausibility checks for results regarding the data 
itself (internal) as well as regarding other data sources 
(external) [17]. A report for the DIMDI on the access to and 
potential uses of data for care research [18] enumerates a 
number of advantages of GKV data has as well as its limi-
tations. This report also considers other social insurance 
carriers, official statistics and federal health reporting, as 
well as private health insurance data.
Overall, the project made it very clear that secondary 
data, such as the data from AOK Baden-Württemberg used 
here, if specifically prepared and analysed, has the poten-
tial to close certain data gaps within a comprehensive dia-
betes surveillance approach. To reach a consensus on the 
set of 40 indicators, the indicators identified during the 
project were compared against the indicators found by the 
diabetes surveillance literature search. The project results 
led to the inclusion of these four additional indicators in 
the indicator set of diabetes surveillance: diabetic neuropa-
thy, diabetic foot syndrome, renal replacement therapy and 
age at diagnosis.
3.1.4  Epidemiologic parameters and projections for dia-
betes surveillance
The constant spread of diabetes poses considerable chal-
lenges to the healthcare system. Beyond taking stock of 
portion of diabetes patients. Over the course of time, the 
guideline-based treatment that diabetes patients receive 
has significantly improved. Continuous participation in 
DMPs increases the chances to achieve quality targets, and 
there is a clear decrease of severe complications for patients 
participating in type 2 DMPs. For diabetes surveillance, 
DMP data from North Rhine-Westphalia is presented to 
demonstrate the achievement of quality targets for both 
type 1 and type 2 diabetes. In future, the different frequen-
cies of target achievement stratified by gender and age 
group over time will be reported and integrated into dia-
betes reporting.
3.1.3  Routine data to measure quality: definitions and 
measurement
As part of this co-operation project, a complete data set 
for one statutory health insurance (AOK Baden-Württem-
berg) was used to analyse to what extent secondary data 
can contribute towards the overall project of establishing 
diabetes surveillance at the RKI.
To start, the aQua Institute for Applied Quality Improve-
ment and Research in Health Care in Göttingen conducted 
a review of literature searching for type 2 diabetes indica-
tors. In a first step it defined inclusion and exclusion crite-
ria. Included were all indicators that can be applied to adult 
type 2 diabetes patients. Indicators of type 1 diabetes or 
gestational diabetes were excluded.
In November 2016, an expert panel took place in Göt-
tingen. With external expertise, an indicator set was agreed 
in consensus. The experts evaluated all the indicators that 
had been found in the search in terms of their relevance 
for diabetes surveillance. The meeting offered room to fur-
Co-operation project results 
indicate increasing case 
numbers by 2040 but also 
improved treatment for 
diabetes patients.
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tions of the trends until 2040, predict increases of over 
50% [20].
3.1.5  Using geocoding services to gain information on 
the obesogenicity of environments
A feasibility study tested the potential of data from online 
geocoding services to be used for the surveillance of envi-
ronmental factors associated with type 2 diabetes. Using 
obesity as an example, initially the literature was searched 
for factors related to an obesogenic environment, i.e. an 
environment that is conducive to obesity [21-23]. Features 
of the environment that previous studies had associated 
positively with obesity were defined as obesogenic factors 
(for example fast food restaurants) and those defined as 
negative as protective factors (such as green areas). Subse-
quently, these factors were operationalised through expert 
interviews (n=4) based on the variables provided by the 
geocoding services Google Maps and OpenStreetMap. 
Using the statistics software R, new automated query scripts 
were developed to download and analyse relevant data in 
particular regarding the specific features of environments.
Site visits and an online search had the objective to val-
idate the data from four pilot areas in Bavaria. This served 
to verify that the place and type of environmental features 
that had been detected were correct and whether there 
were additional relevant features that had been omitted 
from the identified data. The project showed that the 
demands for completeness of data, download capacity and 
the diversity of variables are relevant dimensions to select 
a particular geocoding service. Finally, for the city of Augs-
burg, kernel density estimations and heat maps were pro-
duced and cluster algorithms applied to describe the spa-
current case numbers, resource planning will require the 
most accurate prediction possible of future developments. 
Current estimates for Germany indicate that the number 
of diabetes patients is set to increase sharply in the future, 
these projections are however either based on figures for 
specific age ranges or solely on the data from particular 
statutory health insurances [19]. Due to the diversity of the 
demographic and socioeconomic characteristics of the 
groups insured by different health insurances, basing pre-
dictions on the data provided by individual insurances is 
problematic.
To better predict future figures of people with type 2 dia-
betes, this project applies the age- and gender-specific 
preva lence of type 2 diabetes from the year 2015 to the 
future age structure of the German population until 2040 
as predicted by the Federal Statistical Office [20]. The 
assumed prevalence is thereby based on the data of all 
statu tory health insurances in Germany, or DaTraV data [10].
Assuming that demographic ageing continues, yet that 
the age-specific prevalence of type 2 diabetes for women 
and men remains constant between 2015 and 2040, the 
number of people with type 2 diabetes will increase from 
6.9 million in 2015 to 8.34 million in 2040, which would be 
a 21% increase. Predicting the future number of diabetes 
cases by using current age-specific prevalence is the sim-
plest form to calculate a projection. Improved treatment 
of diabetes patients due to medical progress and the result-
ing longer average life expectancy will very likely lead to a 
rising age-specific prevalence, making the results presented 
here a conservative estimate. More realistic scenarios are 
obtained by modelling the interaction between incidence 
and mortality rates, which, when based on realistic assump-
Initial results, which are 
based on the data of all 
people covered by statutory 
health insurance, indicate an 
increase in documented 
prevalences of type 2 
diabetes from 7.7% (2010) to 
8.1% (2011) for women and 
8.2% to 8.6% for men, 
respectively.
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diabetes will lose less life years than people without dia-
betes compared to 2015. This applies to all age groups. 
Women, in general, will lose less life years than men. 
Assuming an annually decreasing relative death risk 
between 2015 and 2040 would result in a relative decrease 
of YLL of up to 64% over the same period.
The model scenarios in their majority in principle indi-
cate an increase of healthy life years (HLY) for the period 
considered across almost all age groups. One exception 
are the results for the over-80 age group. For example, an 
over-80-year-old man in 2040 can expect on average to live 
another 5 years without diabetes, whereas in 2015 it was 
5.5 years. Our results are in line with the results of interna-
tional studies on changes to diabetes-related morbidity [25]. 
3.1.7  Renal replacement therapy in people with and with-
out diabetes
Renal insufficiency belongs to the severe conditions dia-
betes patients may develop. At advanced stages this is 
treated with renal replacement therapy, which is associ ated 
with higher mortality and costs [26, 27]. For this reason, 
renal replacement therapy has been included as an indica-
tor to diabetes surveillance, with the objective of analysing 
the disease burden over time [4]. However, there is so far 
no long-term data on whether the figures for renal replace-
ment therapy (incidence) have decreased for people with 
and without diabetes in Germany.
So far, the incidence of renal replacement therapy has 
been analysed based on the data from doctors’ surgeries 
in North Rhine-Westphalia [26], as well as from the 
Gmünder Ersatzkasse (statutory health insurance data) of 
people with and without diabetes in the 2000s and pro-
tial distribution of variables. Cartographic analysis was then 
used to identify the areas with a high density of either obe-
sogenic or protective environmental factors. Correspond-
ingly, this study helped develop a suitable method to pre-
pare and represent data from online geocoding services 
for the description of obesogenic environments suitable 
for diabetes surveillance. However, to assess the predictive 
power of this method for actual obesity and/or diabetes 
risks, the method will need to be tested in further surveys 
with population-based data.
3.1.6  Indices relevant to public health and their projec-
tion relative to diabetes
The projection of diabetes-related years of life lost (YLL) 
and healthy life years (HLY) is based on prevalence, inci-
dence and mortality rate ratio (MRR) data. Age- and gen-
der-specific 2010 prevalences [10] were used to calculate 
YLL and HLY between 2015 and 2040 based on different 
scenarios of diabetes incidence and mortality.
As the long-term development of diabetes incidence in 
Germany is unknown, three hypothetical scenarios are cur-
rently being discussed: an unchanging incidence rate and 
an increase or a decrease in the incidence rate by 0.5%, 
respectively. Moreover, the advance of medicine will pre-
sumably lead to a greater decrease in the mortality of dia-
betes patients relative to people without diabetes, so the 
relative mortality risk is varied. We are therefore looking at 
scenarios with an annual 2% decrease in the mortality risk. 
YLL are calculated using a birth cohort framework, HLY by 
applying the Sullivan method [24].
During the period considered, the number of life years 
lost decrease for women and men. In 2040, people with 
A definition was developed 
that will serve as a basis for 
future calculations and 
enhance the reliability and 
comparability of results for 
documented prevalence in 
the context of diabetes 
surveillance.
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2011 for the documented prevalence of type 2 diabetes. 
Prevalent type 2 diabetes was defined as at least one 
assured documented out- or inpatient type 2 diabetes diag-
nosis coded according to the International Statistical Clas-
sification of Diseases and Related Health Problems, 10th 
revision (ICD-10: E11.-).
Together with experts from the diabetes surveillance sci-
entific advisory board and based on the feedback from the 
data processing unit, the results of the query and of co-op-
eration projects served as a starting point to define a ref-
erence analysis to determine documented prevalence 
(Info box 2). In future, this should provide robust results 
on the overall prevalence of diabetes as well as segregated 
by type 1, type 2 and other forms of diabetes mellitus for 
Germany and German federal states. The reference anal-
ysis will apply validation data sets. For one, the number of 
people who receive diabetes medication without having 
been diagnosed with diabetes will be determined. Further-
more, diabetics who according to the data only have a sec-
ondary inpatient diagnosis of diabetes will also be deter-
mined. This validation data set should help to better assess 
the consensually agreed definition.
Irrespective of the results of the reference definition, the 
applied for results for the reporting years 2010 and 2011 
show the DaTraV data potential for diabetes surveillance. 
Information on age, gender and diabetes diagnosis was 
analysed for a total of 66.2 million statutory health insured 
for the year 2010 and 66.4 million for 2011. The results in 
Figure 3 are stratified by gender and year for type 2 
diabetes and evidence an increase in administrative preva-
lence. In women, documented prevalence increased from 
7.7% (2010) to 8.1% (2011) and in men from 8.2% to 8.6%. 
vided results that can be compared well [28]: the age stan-
dardised incidence rate for the population with diabetes 
was between around 190 and 215 per 100,000 person-years, 
for the population without diabetes roughly between 
30 and 40. Therefore, for diabetes patients the risk to have 
renal replacement therapy was around six to eight times 
higher. No significant trend over time was found. During 
the current project, the evaluation of data from doctors’ 
surgeries was expanded to cover the period between 2002 
and 2016. The results are expected in 2019.
Moreover, there are plans to analyse the prevalence and 
incidence of renal replacement therapy in people with and 
without diabetes based on the data of several GKVs across 
Germany during the last decade. The project aims to anal-
yse the possibilities to reliably describe renal replacement 
therapy through diagnoses based on the International Sta-
tistical Classification of Diseases and Related Health Prob-
lems (ICD) using health insurance data. The objective of 
this project is to evaluate the suitability of DaTraV data for 
this project, which as described above contains informa-
tion on all statutory health insured. In a final step, a meet-
ing of experts will discuss the comparability of different 
data sources (doctors’ surgeries, GKV and DaTraV data). 
One particular focus will be to discuss the possibilities to 
standardise the algorithms that apply to define renal 
replacement therapy and renal insufficiency in routine data.
 
3.2  Initial results for the documented prevalence of type 2 
diabetes in DaTraV data
The first DaTraV application by diabetes surveillance 
referred to a comparison of the reporting years 2010 and 
Info box 2: 
Reference definition to define documented preva-
lence of diabetes mellitus in the context of dia-
betes surveillance based on DaTraV data 
Total diabetes 
Denominator: people insured for at least 360 days 
of one year with data on year of birth and gender, 
no insured residing abroad or those opting for 
reimbursement of costs according to section 13 
(2) or section 53 (4) of Book 5 of the German 
Social Code (SGB V). 
Numerator: people with at least two assured out-
patient or at least one inpatient documented ICD-
10 diagnoses of diabetes mellitus (E10.- to E14.-1) 
Type 1 diabetes
Denominator: see above
Numerator: people with at least two assured out-
patient documented ICD diagnoses E10.- or with 
an outpatient assured documented ICD diagnosis 
E10.- and at least one further ambulatory assured 
documented ICD diagnosis diabetes mellitus 
according to E12.- to E14.- or an inpatient docu-
mented ICD-10 diagnosis E10.-
Excluded: people with at least one ambulatory or 
inpatient documented ICD diagnosis E11.-
Type 2 diabetes
Denominator: see above
Numerator: people with at least two outpatient 
assured documented ICD diagnoses E11.- or with 
one outpatient assured documented ICD-10 diag-
nosis E11.- and at least one further outpatient 
assured diagnosis ICD-10 diabetes mellitus accord-
ing to E12.- to E14.- or an inpatient documented 
ICD-10 diagnosis according to E11.-
Excluded: people with at least one outpatient 
assured diagnosis or inpatient documented ICD-10 
diagnosis according to E10.- 
continued on next page
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of the administrative prevalence of diabetes within the 
context of diabetes surveillance (Info box 2).
4.  Discussion
Secondary data is an important element to determine indi-
cators for diabetes surveillance. It can be used to prepare 
time series as a basis for numerous indicators.
In particular, DaTraV data is well suited for the pur-
poses of surveillance, because it is a complete data set 
of all statutory health insured in Germany that is updated 
annually. The planned revision of DaTraV can overcome 
current limitations of this data set such as the transfer of 
diagnosis and medications data also for the year of leav-
ing the GKV system and the current four-year delay. In 
addition, there is an objective to reduce the time required 
to process applications in particular by employing more 
staff. In future, this will ensure an even better depiction 
of regularly repeated observations of the disease burden 
at short intervals.
Meaningfully comparable analyses of secondary data 
require transparent and consensually agreed definitions of 
selection and applicability criteria. The presented reference 
definition to calculate the overall prevalence of diabetes, 
as well as differentiated by type 1, type 2 and other forms 
of diabetes based on DaTraV data is a step towards greater 
transparency. The developed definition thereby is not only 
important for comparisons of prevalence over time, but 
also serves as a reference for further indicators of diabetes 
surveillance. For example, the definition is also used to 
depict numerous diabetes complications, incidence and 
mortality based on DaTraV data.
Furthermore, the results confirm the known age-related-
ness of type 2 diabetes, as for both genders an increase of 
prevalence with age is observed. The results resemble other 
analyses based on DaTraV data [10]. However, the age 
group over 80 is too large to describe the effect of decreas-
ing prevalence among the very old aged over about 85 [8]. 
The definition of diabetes used for Figure 3, which bases 
itself on a definitive out- or inpatient diagnosis in the report-
ing year, differs from the generally used criterion of at least 
two quarterly periods. According to this criterion, a defini-
tive outpatient diagnosis of diabetes must be coded during 
at least two quarters of one year to rule out documentation 
effects. The analysis moreover showed, that for numerous 
cases instead of specific diagnoses of either type 1 or type 
2 diabetes, diagnoses were either unspecific or mutually 
exclusive. For these reasons, in co-operation with experts 
from epidemiology and care, the reference definition 
described below was developed to allow future description 
Info box 2 (Continued): 
Other forms
Denominator: see above
Numerator: people with at least two outpatient 
assured or at least one inpatient documented ICD-
10 diagnosis in groups E10.- to E14.-
Excluded: people who were already assigned to 
type 1 or type 2 diabetes based on the algorithm 
mentioned above.
ICD-10 = International Statistical Classification of Diseases 
and Related Health Problems, 10th revision
E10 = Insulin-dependent diabetes mellitus (type 1 diabetes)
E11 = Non-insulin-dependent diabetes mellitus (type 2 dia-
betes)
E12 = Malnutrition-related diabetes mellitus
E13 = Other specified diabetes mellitus
E14 = Unspecified diabetes mellitus 
An outpatient diagnosis can, depending on docu-
mentation, be a diagnosis that is suspected, related 
to a state following a certain illness (such as a heart 
attack), ruled out or assured. Only diagnoses clas-
sified as assured are used here to define documen-
ted prevalence.
Validation data sets for total diabetes
1)  people who have been prescribed antidiabetic 
drugs without documented diabetes  
2)  people with only an inpatient secondary diag-
nosis
Figure 3 
Comparison of the documented prevalence 
of type 2 diabetes mellitus for the 
years 2010 and 2011 according to gender
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